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OBJECTIVES The purpose of this study was to examine the effects of glycoprotein (GP) IIb/IIIa antagonists
(abciximab, eptifibatide, and tirofiban) and other inhibitors on translocation of CD40L from
intraplatelet stores to the platelet surface and on the release of soluble CD40L (sCD40L)
from platelets.
BACKGROUND CD40L is a proinflammatory and prothrombotic ligand in the tumor necrosis factor family.
METHODS Platelet surface CD40L was measured by flow cytometry, and sCD40L was measured by
enzyme-linked immunosorbent assay.
RESULTS Translocation of CD40L from intraplatelet stores to the platelet surface was not inhibited by
GP IIb/IIIa antagonists. However, release of sCD40L from the surface of activated platelets
was inhibited by GP IIb/IIIa antagonists in a dose-dependent manner, in concert with
inhibition of PAC1 binding to platelets (a surrogate marker for fibrinogen binding). Release
of sCD40L from activated platelets was also markedly reduced in Glanzmann platelets
(deficient in GP IIb/IIIa). Ethylenediaminetetraacetic acid was an effective inhibitor of
sCD40L release, but only when added before platelet activation. Both cytochalasin D (an
inhibitor of actin polymerization) and GM6001 (an inhibitor of matrix metalloproteinases
[MMPs]) inhibited the release of sCD40L from platelets when added before, as well as 3 min
after, platelet activation. However, neither cytochalasin D nor GM6001 affected translocation
of CD40L to the platelet surface.
CONCLUSIONS The GP IIb/IIIa antagonists inhibit release of sCD40L from activated platelets. Release of
sCD40L from platelets is regulated, at least in part, by GP IIb/IIIa, actin polymerization, and
an MMP inhibitor-sensitive pathway. In addition to their well-characterized inhibition of
platelet aggregation, GP IIb/IIIa antagonists may obviate the proinflammatory and pro-
thrombotic effects of sCD40L. (J Am Coll Cardiol 2004;43:2319–25) © 2004 by the
American College of Cardiology Foundationp
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in addition to their well-known function in hemostasis and
hrombosis, platelets play an important role in inflammation
1). Platelets contain a variety of inflammatory modula-
ors—including CD40 ligand (CD40L, CD154), platelet-
erived growth factor, platelet factor 4, RANTES (regu-
ated upon activation, normal T-cell expressed and
See page 2326
ecreted), thrombospondin, and transforming growth factor
eta—that are released upon platelet activation. Atheroscle-
osis is a chronic inflammatory disease, and the CD40/
D40L interaction has a central role in the pathogenesis of
therosclerosis (2).
CD40L, a member of the tumor necrosis factor family, is
ot expressed on the resting platelet surface. However,
enn et al. (3) demonstrated that platelets translocate
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Manuscript received July 14, 2003; revised manuscript received December 16,o003, accepted December 23, 2003.reformed intraplatelet stores of CD40L to the platelet
urface within seconds of activation in vitro and in the
resence of thrombus formation in vivo. Furthermore,
latelet surface CD40L interacts with endothelial cell
D40 to induce a thromboinflammatory reaction of endo-
helial cells (3). Activated platelets also release large
mounts of soluble CD40L (sCD40L) over a period of
inutes to hours (4–6). Indeed, platelets appear to be the
redominant source of circulating sCD40L (5). The
CD40L released from platelets during thrombosis has
hree reported functions (7): 1) induction of the production
nd release of proinflammatory cytokines from vascular cells
nd of matrix metalloproteinases (MMPs) from resident
ells in the atheroma (although not all studies agree on this
oint [5]); 2) stabilization of arterial thrombi (8); and 3)
nhibition of re-endothelialization of injured blood vessels
9).
In the present study, we examined the effects of GP
Ib/IIIa antagonists (abciximab, eptifibatide, and tirofiban)
nd other inhibitors on the translocation of CD40L from
ntraplatelet stores to the platelet surface and on the release
f sCD40L from platelets.
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lood collection. This study was approved by the institu-
ional review board of the University of Massachusetts
emorial Health Care, and subjects gave written informed
onsent. Peripheral blood was collected from healthy donors
r patients with Glanzmann thrombasthenia (10) into
ndotoxin-free 3.2% sodium citrate Vacutainer tubes (Bec-
on Dickinson, San Jose, California), after discarding the
rst 2 ml of drawn blood. No donor or patient had received
ny drug known to affect platelet function (including aspi-
in, cyclooxygenase inhibitors, statins) within the previous
0 days. Platelet-rich plasma (PRP) was prepared by cen-
rifuging the blood at 150 g for 12 min at 22°C.
low cytometry. The PRP was diluted 1:5 (to prevent
latelet aggregation) with modified HEPES Tyrode’s (HT)
uffer (NaCl 137 mM, KCl 2.8 mM, MgCl2 1 mM,
aHCO3 12 mM, Na2HPO4 0.4 mM, glucose 5.5 mM,
EPES 10 mM, pH 7.4) and (to prevent Fc-mediated
ffects) incubated at 22°C for 10 min with the FcRIIa
CD32) blocking antibody IV.3 (Medarex, Princeton, New
ersey) 2.5 g/ml. The PRP was then incubated at 22°C for
0 min with either HT buffer alone, abciximab 6.4 g/ml,
ptifibatide 1.0 g/ml, tirofiban 50 ng/ml, ethylenediamine-
etraacetic acid (EDTA) 5 mM, GM6001 (also known as
alardin, an inhibitor of MMPs [11]) (Calbiochem, San
iego, California) 30 M, or cytochalasin D (an inhibitor
f actin polymerization [12]) (Sigma, St. Louis, Missouri)
0 M. (Assays with GM6001 and cytochalasin D included
.3% dimethyl sulfoxide.) Samples were then incubated
ith or without 50 M iso(S)FLLRN (iso-thrombin re-
eptor activating peptide) (Multiple Peptide Systems, San
iego, California) and with a saturating concentration of
ither the CD40L-specific phycoerythrin (PE)-conjugated
onoclonal antibody 24-31 (Ancell, Bayport, Minnesota)
or the same concentration of PE-conjugated mouse isotype
ontrol IgG1 [Pharmingen, San Diego, California]) for 1 h
t 37°C or a cocktail of the activated GP IIb/IIIa-specific
uorescein isothiocyanate (FITC)-conjugated monoclonal
ntibody PAC1 (Becton Dickinson) and the GP IIIa-
pecific peridinin chlorophyll protein (PerCP)-conjugated
onoclonal antibody RUU-7F12 (Becton Dickinson) for 3
Abbreviations and Acronyms
EDTA  ethylenediaminetetraacetic acid
ELISA  enzyme-linked immunosorbent assay
FITC  fluorescein isothiocyanate
GP  glycoprotein
HT  HEPES Tyrode’s buffer
MMPs  matrix metalloproteinases
PCI  percutaneous coronary intervention
PE  phycoerythrin
PerCP  peridinin chlorophyll protein
PRP  platelet-rich plasma
sCD40L  soluble CD40 ligandin at 22°C. Samples were then fixed with 1% formalin mPolysciences, Eppelheim, Germany) for 10 min at 22°C.
amples labeled with 24-31 were then washed by centrifu-
ation at 1,200 g for 7 min, and the formalin supernatant
as aspirated. The platelet pellet was then resuspended in
T buffer containing the GP IIIa-specific FITC-
onjugated monoclonal antibody Y2/51 (DAKO, Carpin-
eria, California) 0.5 g/ml (or, for Glanzmann samples,
he GPIX-specific PerCP-conjugated monoclonal antibody
eb1 [Becton Dickinson] 1.25 g/ml) and incubated at
2°C for 10 min. Samples were then diluted in 1% formalin
ntil analysis by flow cytometry. Flow cytometry was per-
ormed in a FACSCalibur (Becton Dickinson) with stan-
ard filter configuration and Cell Quest software. Platelets
ere identified by their characteristic forward and orthog-
nal light scatter properties and by labeling with a platelet-
pecific monoclonal antibody (FITC-Y2/51, PerCP-RUU-
F12, or PerCP-Beb1). Platelet surface CD40L and
ctivated GP IIb/IIIa was measured by mean fluorescence
ntensity (PE and FITC, respectively). Neither Y2/51 nor
UU-7F12 block the binding of abciximab, eptifibatide,
irofiban, or PAC1.
nzyme-linked immunosorbent assay (ELISA). Platelet
ounts in PRP were normalized to 300,000 platelets per l.
he PRP was then incubated (22°C, 20 min) with various
oncentrations of a GP IIb/IIIa antagonist, EDTA 5 mM,
M6001 30 M, cytochalasin D 60 M, or HT buffer
lone. Samples were incubated (37°C, 1 h) with or without
0 M isoTRAP. In some experiments, EDTA 5 mM,
M6001 30 M, or cytochalasin D 60 M was added 3
in after the addition of the 50 M isoTRAP. After
ctivation, the samples were centrifuged (8,000 g, 3 min,
2°C), the supernatants were transferred to a clean tube and
entrifuged again (8,000 g, 3 min, 22°C), and the subse-
uent supernatants were transferred to a clean tube. These
upernatants were then immediately tested for sCD40L by
LISA (Bender MedSystems, San Bruno, California). The
LISA was set up according to the package insert except
hat plasma samples were diluted 1:1 (50 l:50 l) with
ssay buffer. The average of duplicate samples was recorded.
o determine the amount of released sCD40L, the
CD40L concentration of samples without added isoTRAP
as subtracted from the sCD40L concentration of samples
ith added isoTRAP. The range of 0.33 to 4.84 ng/ml in
he background sCD40L of our normal donors and Glanz-
ann thrombasthenia donors is consistent with the
CD40L range of 0.03 to 4.0 ng/ml obtained from a panel
f 40 healthy donors (Bender MedSystems, product insert).
his normal variability in the background sCD40L of both
he normal donors and the Glanzmann thrombasthenia
onors does not detract from our conclusions, because each
onor and patient acted as his or her own control. The PRP
ncubated for 40 min in the absence of an agonist resulted in
o increase in sCD40L over the background sCD40L in the
ame donor’s fresh platelet-poor plasma.
tatistical analysis. Significance (p  0.05) was deter-
ined by two-tailed t test.
RA
m
(
f
i
t
t
a
n
c
s
b
o
i
r
d
t
p
v
l
n
o
r
A
i
t
s
F
b
d
m
m

w
p
S
a
fl
Y
c
t
t
t
i
F
i
p
m
s

I
I
l
a
t
e
d
w
i
s
2321JACC Vol. 43, No. 12, 2004 Furman et al.
June 16, 2004:2319–25 Regulation of CD40L Release From PlateletsESULTS
ctivation of platelets with 50 M isoTRAP resulted in a
arked increase in the platelet surface expression of CD40L
Fig. 1). This activation-dependent translocation of CD40L
rom intraplatelet stores to the platelet surface was not
nhibited by pharmacologically relevant concentrations of
he GP IIb/IIIa antagonists abciximab, eptifibatide, or
irofiban (Fig. 1). However, the release of sCD40L from
ctivated platelets was inhibited in a dose-dependent man-
er by abciximab, eptifibatide, and tirofiban (Fig. 2), in
oncert with inhibition of PAC1 binding to platelets (a
urrogate marker for fibrinogen binding [13]) (Fig. 2).
To further assess the role of GP IIb/IIIa in the redistri-
ution of CD40L molecules, we next examined the platelets
f two patients with Glanzmann thrombasthenia (an inher-
ted deficiency of GP IIb/IIIa [10]). Consistent with our
esults with GP IIb/IIIa antagonists, the activation-
ependent translocation of CD40L from intraplatelet stores
o the platelet surface was not reduced in Glanzmann
latelets (Fig. 3A), but the release of sCD40L from acti-
ated platelets was markedly reduced in Glanzmann plate-
ets (Fig. 3B).
Because sCD40L is released from washed platelets (4,5),
o plasma component is required for its cleavage. Members
f the tumor necrosis factor family of molecules have been
igure 1. Translocation of CD40L to the platelet surface is not inhibited
y glycoprotein IIb/IIIa receptor antagonists. The platelet-rich plasma
iluted 1:5 in modified HEPES Tyrode’s buffer was incubated (22°C, 10
in) with an FcRIIa blocking antibody, and then incubated (22°C, 20
in) with either buffer alone, abciximab (6.4 g/ml), eptifibatide (1.0
g/ml), or tirofiban (50 ng/ml). Samples were then activated (37°C, 1 h)
ith 50 M isoTRAP (except the “no agonist” sample) and the
hycoerythrin-conjugated CD40L-specific monoclonal antibody 24-31.
amples were then fixed with 1% formalin (22°C, 10 min), washed once,
nd the platelet pellet was gently resuspended in buffer containing the
uorescein isothiocyanate-conjugated CD61-specific monoclonal antibody
2/51. Samples were analyzed for platelet surface CD40L by flow
ytometry. Data are mean  SEM, n  4. As indicated by the asterisk,
here was a significant difference between the buffer/isoTRAP sample and
he buffer/no agonist sample. There were no significant differences between
he buffer/isoTRAP sample and abciximab/isoTRAP, eptifibatide/
soTRAP, and tirofiban/isoTRAP samples.eported to be cleaved by calcium-dependent MMPs and by cDAMs, both of which are inhibited by hydroxamate
nhibitors of MMPs (11,14). Therefore, to further examine
he mechanism of the redistribution of platelet CD40L and
CD40L release, we assessed the effects of EDTA (a strong
igure 2. The release of sCD40L from the surface of activated platelets is
nhibited by glycoprotein (GP) IIb/IIIa antagonists. The platelet-rich
lasm (with platelet count adjusted to 300,000/l) was incubated (22°C, 20
in) with the indicated concentrations of GP IIb/IIIa antagonist (note log
cale). A small aliquot was removed and incubated (22°C, 3 min) with 50
M isoTRAP, fluorescein isothiocyanate-conjugated activated GP IIb/
IIa-specific monoclonal antibody PAC1, and PerCP-conjugated GP
IIa-specific monoclonal antibody RUU-7F12, then fixed with 1% forma-
in and analyzed by flow cytometry. The remaining aliquot was then
ctivated (37°C, 1 h) with 50 M isoTRAP without stirring, centrifuged
wice, and the supernatants were tested in duplicate for sCD40L by
nzyme-linked immunosorbent assay. Values for “Released sCD40L” were
etermined by subtracting sCD40L values obtained from samples that
ere not isoTRAP-activated from values obtained from samples that were
so-TRAP activated. Data are mean  SEM, n  3. Asterisks indicate
ignificance as compared with samples with no GP IIb/IIIa antagonist.alcium chelator) and GM6001 (a hydroxamate inhibitor of
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ochalasin D (an inhibitor of actin polymerization [12]).
either EDTA, cytochalasin D nor GM6001 inhibited the
ctivation-dependent translocation of CD40L from in-
raplatelet stores to the platelet surface (Fig. 4). (In fact,
DTA resulted in a modest increase in platelet surface
D40L.) The EDTA was an effective inhibitor of sCD40L
elease, but only when present before platelet activation
Fig. 5A). When EDTA was added 3 min after platelet
ctivation with 50 M isoTRAP, no inhibition of sCD40L
as observed (Fig. 5B). Both cytochalasin D and GM6001
arkedly inhibited the release of sCD40L from platelets
hen added before, as well as 3 min after, platelet activation
Fig. 5).
ISCUSSION
ur results demonstrated the following: 1) GP IIb/IIIa
ntagonists (abciximab, eptifibatide, and tirofiban) inhibit
he release of sCD40L from activated platelets and there-
ore, in addition to their well characterized inhibition of
latelet aggregation, they may obviate the proinflammatory
igure 3. The activation-dependent translocation of CD40L to the plate-
et surface is not reduced in Glanzmann platelets (A), but the release of
CD40L from the surface of activated platelets is markedly reduced in
lanzmann platelets (B). (A) Platelet surface CD40L, in the presence of
0 M isoTRAP, was measured as in Figure 1. (B) Released sCD40L in
latelet rich plasma was measured as in Figure 2. Data are mean  SEM,
 3 for normal control samples and mean of n  2 for Glanzmann
hrombasthenia. Asterisks indicate significance as compared with normal
ontrol samples.15–18) and prothrombotic effects (8) of sCD40L. 2) Aelease of sCD40L from platelets is regulated, at least in
art, by GP IIb/IIIa, actin polymerization, and an MMP
nhibitor-sensitive pathway. 3) Translocation of CD40L
rom intraplatelet stores to the platelet surface is not
nhibited by GP IIb/IIIa antagonists and is not regulated by
P IIb/IIIa or actin polymerization.
Soluble CD40L ligand is prothrombotic via stabilization
f arterial thrombi by a beta3-integrin (GP IIIa)-dependent
echanism (8). The sCD40L has been reported to be
roinflammatory via induction of leukocyte chemokine
roduction (15) and endothelial cell adhesive proteins (16).
lthough the proinflammatory effects of recombinant
CD40L in vitro (15–17) and in vivo (18) are well de-
cribed, Henn et al. (5) were unable to document such
ffects with natural sCD40L in vitro. Elevated plasma levels
f sCD40L have been demonstrated in thrombotic and/or
nflammatory states: unstable angina (4), percutaneous cor-
nary intervention (PCI) (4), cardiopulmonary bypass (19),
eripheral arterial occlusive disease (20), essential thrombo-
ythemia (21), reactive thrombocytosis (21), and systemic
upus erythematosus (22). High plasma concentrations of
CD40L may be associated with increased cardiovascular
isk in apparently healthy women (23). Platelets appear to
e the predominant source of circulating sCD40L (5). The
levated plasma levels of sCD40L in unstable angina and
uring PCI in the absence of GP IIb/IIIa antagonist
herapy (4), therefore, are of particular relevance to the
resently described inhibition of sCD40L release from
latelets by GP IIb/IIIa antagonists (abciximab, eptifi-
atide, tirofiban), because these agents are now standard
herapy for unstable angina (24) and during PCI (25). The
CD40L is only released when platelets are activated (4–6),
hat is, at sites of local thrombosis. The presently described
nhibitory effects of GP IIb/IIIa antagonists on sCD40L
elease from activated platelets would therefore occur most
rominently in vivo at the site or sites of greatest potential
enefit. Thus, the present findings suggest that GP IIb/IIIa
ntagonist therapy, in addition to its well-known inhibition
f platelet aggregation, may be of benefit in patients with
nstable angina and during PCI via an additional mecha-
ism of action: inhibition of the prothrombotic (8) and
roinflammatory (15–18) effects of sCD40L. Because all
hree Food and Drug Administration-approved GP IIb/IIIa
ntagonists (abciximab, eptifibatide, and tirofiban) are able
o inhibit sCD40L release, our results do not differentiate
etween these agents with respect to their ability to produce
linically relevant inhibition of inflammation. Heeschen et
l. (26) recently demonstrated that measurement of
CD40L in the first 12 h after the onset of ischemic
ymptoms in patients with unstable angina identifies a
ubgroup of patients that has a much greater clinical benefit
rom abciximab treatment.
Consistent with the present study, Nannizzi-Alaimo et
l. (27), in a study published after the completion of the
resent work, reported that the three Food and Drug
dministration-approved GP IIb/IIIa antagonists inhibit
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June 16, 2004:2319–25 Regulation of CD40L Release From Plateletshe release of sCD40L from platelets in vitro. These
nvestigators (27) also reported that suboptimal doses of
hese three antagonists (that resulted in between 0% and
0% platelet aggregation) potentiated the release of
CD40L from platelets in vitro, raising the possibility that
he proinflammatory effects of sCD40L could explain the
egative results of the Global Utilization of Streptokinase
nd Tissue Plasminogen Activator for Occluded Arteries
GUSTO IV) trial of abciximab (28). However, our exper-
ments used doses of GP IIb/IIIa antagonist that under our
xperimental conditions resulted in a similar degree of
nhibition of platelet aggregation yet did not potentiate
CD40L release (Fig. 2). This apparent discrepancy be-
ween our results and those of Nannizzi-Alaimo et al. (27)
ay result from technical differences, including anticoagu-
ants (citrate vs. D-phenylalanyl-prolyl-arginine), agonists
50 M isoTRAP vs. 5 M thrombin receptor activating
eptide), and unstirred versus stirred conditions. The en-
anced inhibition of sCD40L release by eptifibatide and
irofiban compared with abciximab observed in the study by
annizzi-Alaimo et al. (27) was likely due to the fact that
hese investigators initiated platelet activation and GP
Ib/IIIa inhibition simultaneously by adding PRP to a
ixture of platelet agonist and GP IIb/IIIa antagonist.
ecause abciximab has a slower on rate than the small
olecule inhibitors eptifibatide and tirofiban (29), processes
ediating the release of sCD40L may already be initiated
efore complete receptor blockade by abciximab. In our
xperiments, GP IIb/IIIa antagonists were preincubated
ith platelets for 20 min at room temperature before
latelet activation, thereby allowing adequate time for all
P IIb/IIIa antagonists to reach equilibrium. This latter
pproach may be more relevant to the clinical situation in
hich GP IIb/IIIa antagonists are dosed at high levels
igure 4. The ethylenediaminetetraacetic acid (EDTA), cytochalasin D,
nd GM6001 do not inhibit the activation-dependent translocation of
D40L to the platelet surface. Platelet surface CD40L, in the presence of
0 M isoTRAP and either no inhibitor, EDTA 5 mM, cytochalasin D 60
M, or GM6001 30 M, was measured as in Figure 1. Data are mean 
EM, n  4. The asterisk indicates significance as compared with no
nhibitor.efore procedures that activate platelets. Thus, plasma fiCD40L in patients after in vivo treatment with abciximab
r eptifibatide, measured when receptor occupancy was low,
as not elevated compared with pretreatment levels (30).
In contrast to both our findings and those of Nannizzi-
laimo et al. (27) with intravenous GP IIb/IIIa antagonists,
ondlo et al. (31) reported that oral GP IIb/IIIa antagonists
roxifiban and orbofiban) in pharmacologically relevant
oses do not affect the release of sCD40L from platelets in
itro. The resultant lack of inhibition of the proinflamma-
ory (15–18) and prothrombotic effects (8) of sCD40L may
ontribute to the reported lack of clinical effectiveness of
ral GP IIb/IIIa antagonists (32). Clopidogrel, a thienopy-
idine, completely abolishes adenosine diphosphate-induced
xpression of platelet surface CD40L (33), but the mecha-
ism is via blockade of the P2Y12 adenosine diphosphate
eceptor, not via a direct effect of clopidogrel on CD40L.
Our results also document a heretofore unrecognized
efect in patients with Glanzmann thrombasthenia: a lack
f activation-dependent release of sCD40L from platelets
Fig. 3B). The biologic and/or clinical significance of this
igure 5. The ethylenediaminetetraacetic acid (EDTA), cytochalasin D,
nd GM6001 inhibit the release of sCD40L from the surface of activated
latelets. Released sCD40L in platelet rich plasma, in the presence of 50
M isoTRAP and either no inhibitor, EDTA 5 mM, cytochalasin D 60
M, or GM6001 30 M, was measured as in Figure 2. (A) Inhibitors
dded before isoTRAP. (B) Inhibitors added 3 min after isoTRAP. Data
re mean SEM, n 3. Asterisks indicate significance as compared with
o inhibitor.nding remains to be determined. Patients with Glanzmann
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Regulation of CD40L Release From Platelets June 16, 2004:2319–25hrombasthenia appear to have higher platelet surface ex-
ression of CD40L (Fig. 3A). A trivial explanation for this
ould be that the platelet surface CD40L is more accessible
o the detecting antibody owing to the lack of platelet
urface GP IIb/IIIa in Glanzmann thrombasthenia. An
lternate explanation is that, because translocation of
D40L from intraplatelet stores to the platelet surface and
roteolysis of platelet surface CD40L is probably occurring
oncurrently, the higher platelet surface expression of
D40L in patients with Glanzmann thrombasthenia re-
ects decreased proteolysis. This latter explanation may also
ccount for the modest increase in the platelet surface
xpression of CD40L in experiments with EDTA (Fig. 4)
nd the statistically insignificant increases in the platelet
urface expression of CD40L in experiments with abcix-
mab and eptifibatide (Fig. 1).
In human T cells, CD40L is processed into its soluble
orm in intracellular microsomes (34). However, as inde-
endently demonstrated by three groups of investigators
5,27,35), platelet lysates, unlike T-cell lysates, demonstrate
ull length but not cleaved forms of CD40L. Thus, the
ntracellular pool of CD40L contains no sCD40L. Al-
hough the release of sCD40L from platelets is activation-
ependent, sCD40L release is not the direct result of 
ranule secretion because the time frames are different. The
elease of CD40L is much slower (maximal at approxi-
ately 45 min [5,6,27]) than alpha granule release (maximal
t approximately 1 min) (36). Henn et al. (5) reported that
D40 is constitutively expressed on platelets, and that the
nteraction of CD40 with CD40L on the surface of acti-
ated platelets is required for proteolysis of sCD40L. The
resent study suggests that the GP IIb/IIIa complex (inte-
rin IIb3) augments the release of sCD40L. Thus, Glanz-
ann thrombasthenia platelets and normal platelets treated
ith fibrinogen-blocking GP IIb/IIIa antagonists have re-
uced activation-dependent sCD40L release (Figs. 2 and
B). These findings may reflect the lack of the normal
outside-in” signaling initiated by fibrinogen binding to
ctivated GP IIb/IIIa (37). Alternately, maximal release of
CD40L may require cell-cell contact, and this is disrupted
n Glanzmann thrombasthenia and by GP IIb/IIIa antag-
nist therapy. Although sCD40L has been shown to bind to
he activated GP IIb/IIIa complex via the lysine-arginine-
lutamic acid (KGD) peptide sequence of CD40L (8),
ncleaved platelet membrane CD40L is unlikely to bind to
P IIb/IIIa by this mechanism because the KGD sequence
f CD40L is located immediately adjacent to the trans-
embrane domain (34), whereas the RGD (and KGD)
inding site appears to be located in the head region of GP
Ib/IIIa (38). However, recent studies by Takagi et al. (39)
uggest that the molecule may assume variably bent confor-
ations. Because the orientation of the transmembrane
omain and extracellular “legs” are uncertain, it is impossi-
le to assign a height to the ligand binding region. In any
vent, this three-dimensional arrangement would not pre-ent GP IIb/IIIa on one platelet from binding to the KGD
equence in uncleaved CD40L on another platelet.
Platelet activation results in fibrinogen binding to the GP
Ib/IIIa complex (37), which results in activation of the
ytoskeleton via actin polymerization (37) and, we hypoth-
size based on our results with cytochalasin D (Fig. 5),
rafficking of the putative CD40L-cleaving protease to the
latelet surface. Consistent with this hypothesis, EDTA,
hen added before the platelet agonist, inhibits the initial
inding of fibrinogen, the subsequent signaling to the
ytoskeleton, movement of the protease to the platelet
urface, and therefore release of sCD40L (Fig. 5A). When
DTA was added after fibrinogen binding (i.e., 3 min after
gonist addition), EDTA was ineffective in inhibiting the
elease of sCD40L (Fig. 5B), suggesting that: 1) signals
nitiating trafficking of the protease had already occurred
nd/or 2) the putative protease is not divalent cation-
ependent. Because most metalloproteinases are divalent
ation-dependent, an alternate possibility is that, although
DTA inhibits the activation of the putative CD40L-
leaving metalloproteinase, once the enzyme has been acti-
ated and engages CD40L at the cleavage site, removal of
ivalent cations cannot prevent proteolysis. As predicted by
ur hypothesis, actin polymerization is still required post-
ctivation because addition of cytochalasin D 3 min after the
gonist (like addition of cytochalasin D before the agonist)
till effectively blocked sCD40L release (Fig. 5). Irrespective
f whether it was added before or after the agonist,
M6001 inhibited the release of sCD40L (Fig. 5) because
M6001 is a direct inhibitor of the metalloproteinase that
utatively cleaves CD40L. Consistent with these findings,
in et al. (6) reported that the simultaneous addition of
hrombin and KB8301, another metalloproteinase inhibitor,
nhibited the thrombin-induced release of sCD40L from
latelets.
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